Communicators

are winners!

More News

08.07.2024
Positive Efficacy Data from Murdoch Children’s Research Institute in Study against WHO Priority Pathogen Acinetobacter baumannii
28.06.2024
Recce Pharmaceuticals Reports Positive Data From Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial of RECCE® 327
24.06.2024
Recce Pharmaceuticals Receives Ethics Approval to Centralise and Broaden RECCE® 327 Gel Clinical Trials across all Topical Bacterial Skin Infections
19.06.2024
Further R&D Rebate Approved
18.06.2024
RECCE® 327 added to The World Health Organization’s List of Antibacterial Products in Clinical Development
11.06.2024
Cohort Dosing Complete – Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial
15.05.2024
First Participants Dosed in Next Cohort - Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial
09.05.2024
Positive Efficacy Data from Murdoch Children’s Research Institute in Pilot Study for Lung Infections
07.05.2024
China Patent Granted for RECCE® Anti-Infectives
16.04.2024
Recce Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)